Rachel Sanborn, MD
Enriched profileCo-Director, Thoracic Oncology Program; Leader, Phase I Clinical Trials Program · Earle A. Chiles Research Institute
Rachel Sanborn is Co-Director, Thoracic Oncology Program; Leader, Phase I Clinical Trials Program at Earle A. Chiles Research Institute. OpenAlex indexes 301 publications with 9,353 citations (h-index 39); ClinicalTrials.gov lists 13 registered studies with this person as an investigator.
Data verified 14 Aug 2026
Overview
Updated 1 Sept 2026
Rachel Sanborn, MD, is Co-Director, Thoracic Oncology Program at Earle A. Chiles Research Institute, Providence Cancer Institute (Providence Cancer Center), Portland, OR. The public record shows 301 publications with 9,353 citations (h-index 39), centered on Lung Cancer (NSCLC/SCLC), Kidney Cancer / RCC. It also documents an investigator role on 13 registered clinical trials, industry payments reported by 23 companies.
- Most recent indexed publication: 2026 · Journal of clinical oncology
- Top research focus: Lung Cancer (NSCLC/SCLC)
- 13 registered trials on ClinicalTrials.gov
- Open Payments reporting from 23 companies
Generated from the cited public record · current as of 1 Sept 2026. Every fact links its source below.
Indications focus
from trials led + research topicsResearch focus
OpenAlex concept fingerprintDrugs & molecules
across trials, industry payments and publicationsWorks with
trial sponsors and companies reporting paymentsScholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID; 22 in PubMed.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingFederally funded research awards.
Contact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
Telephone
Practice address and telephone from the federal NPPES registry.
Sign in to view contact details →Clinical trials
Updated 1 Sept 2026
Listed as an investigator on 13 registered studies on ClinicalTrials.gov. The most recent:
- Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors
Sponsor: SystImmune Inc.
Industry payments
Updated 1 Sept 2026
23 companies reported payments to CMS in program years 2021–2025. These are public disclosures, not judgments. The latest:
- Merck Sharp & Dohme LLCProgram year20258 payments$10,547openpaymentsdata.cms.gov ↗
- Janssen Biotech, Inc.Program year20257 payments$10,534openpaymentsdata.cms.gov ↗
- PFIZER INC.Program year20254 payments
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Nervous system
31.6%Phenothiazine12.4%Prochlorperazine Maleate100%Part D≥27 patientsAtypical Antipsychotic8.9%Olanzapine100%Part D≥11 patientsCancer & immunology
25.9%Kinase inhibitor17.4%Tagrisso100%Part D<11 patientsB-Raf serine-threonine kinase (BRAF) inhibitors4.3%Braftovi100%Part D<11 patientsSensory organs
25.2%Corticosteroid25.2%Dexamethasone100%Part D≥25 patients
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
We didn't find any NIH-funded research awards for this person in NIH RePORTER. Why? →
Publications
Updated 1 Sept 2026
Their five most recent publications, matched to their ORCID record and linked to PubMed.
- First-in-Human, Phase I Study of Sigvotatug Vedotin, an Integrin Beta-6-Directed Antibody-Drug Conjugate: Results From Dose Expansion in Advanced Non-Small Cell Lung Cancer.
Journal of clinical oncology
Clinical Trial2026 - Phase 1 Study of INBRX-105, a TNFRSF9 (4-1BB) and PD-L1 Bispecific Antibody, in Patients with Select Solid Tumors.
Cancer research communications
Clinical Trial2026 - Efficacy and safety of garsorasib in patients with KRAS G12C-mutated advanced pancreatic cancer.
British journal of cancer
Clinical Trial2026 - Updated Overall Survival Analysis From the Phase II PHAROS Study of Encorafenib Plus Binimetinib in Patients With BRAF V600E-Mutant Metastatic Non-Small Cell Lung Cancer.
Journal of clinical oncology
Clinical Trial2025 - Garsorasib, a KRAS G12C inhibitor, with or without cetuximab, an EGFR antibody, in colorectal cancer cohorts of a phase II trial in advanced solid tumors with KRAS G12C mutation.
Signal transduction and targeted therapy
Clinical Trial2025
Online presence
Updated 1 Sept 2026
This person's own public accounts first, then places where others mention them. Two different things, listed separately.
Owned accounts
public accounts run by this person- Doximity
doximity.com/pub/rachel-sanborn-md
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →doximity.com ↗ - LinkedIn
linkedin.com/in/rachel-sanborn-md-0583ab304
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →linkedin.com ↗ - X / Twitter
x.com/rachelsanbornmd
Mentions by others
where others cite or feature them- Other
foundation.providence.org/oregon/portland/about-us/news-stories/dr-rachel-sanborn-honored-by-the-american-lung-association-leads-clinical-trials-that-result-in-drug-approval-and-new-hope-for-patients
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foundation.providence.org ↗ - X / Twitter
x.com/ChilesResearch
We list an account only when the public record ties it to this person. verified means we've confirmed the match in more than one place; provisional means it looks right but we're still confirming.
Background & recognition
Updated 1 Sept 2026
Credentials, appointments and honors, newest first, each linked to the public source it came from.
Education
degrees and training on record- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
- Board Certified
Internal Medicine (American Board of Internal Medicine)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗ - Board Certified
Medical Oncology
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗ - BA
Cornell College
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →lung.org ↗
Editorial & leadership roles
journal and society appointments- Co-Director
Thoracic Oncology Program, Earle A. Chiles Research Institute, Providence Cancer Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗ - Leader (Director)
Phase I Clinical Trials Program, Earle A. Chiles Research Institute
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →pub.orcid.org ↗ - Member
Providence Health & Services Institutional Review Board
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
Awards & honors
honors on the public record- 2024 American Lung Association of the Pacific Northwest Breathe Easy Gala Honoree
recognized for efforts to improve lung cancer outcomes, reduce stigma, enable earlier detection, and reduce lung cancer incidence
2024verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →foundation.providence.org ↗
Secondary affiliations
appointments beyond the home institution- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
- verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →providence.org ↗
Media & interviews
press, podcasts and appearances- GRACE (Global Resource for Advancing Cancer Education) Faculty
recurring video contributor on lung cancer topics (e.g. "Basics of Small Cell Lung Cancer")
provisionalFound in a cited public source but not yet independently corroborated. Published as a labeled candidate and queued for verification.How we verify →cancergrace.org ↗ - Video interview: "Rachel E. Sanborn, MD, on NSCLC: Maximizing the Benefits of Targeted Therapies for EGFR-Mutated Disease"
The ASCO Post, ASCO20 Virtual Scientific Program
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →ascopost.com ↗ - Video contributor
Targeted Oncology, "Sanborn Covers Recently Presented Trials Supporting Immunotherapy in Frontline NSCLC" (live case-based peer perspectives)
verifiedCorroborated by findmyKOL. We matched this record across two or more independent public sources (or a verified ORCID / NPI identifier bridge) before attributing it to this person.How we verify →targetedonc.com ↗
Every item links to where we found it. verified means we've confirmed it in more than one place; provisional means we found it and are still confirming.
Similar KOLs
Other experts from the same institution or the same specialty.
Pasi Janne, MD, PhD
Dana-Farber Cancer Institute
Julie Brahmer, MD
Johns Hopkins University School of Medicine
Enriqueta Felip, MD, PhD
Vall d'Hebron Institute of Oncology (VHIO)
Funda Meric-Bernstam, MD
The University of Texas MD Anderson Cancer Center